{"title":"A Mechanism of Cancer Cell Cytotoxicity of Near-Infrared Photoimmunotherapy","authors":"Kazuhide Sato","doi":"10.2530/jslsm.jslsm-41_0020","DOIUrl":null,"url":null,"abstract":"Near-infrared photoimmunotherapy (NIR-PIT) is a recently developed next-generation cancer photo-target therapy that combines the specificity of intravenously injected antibodies for targeting tumors with toxicity induced by photoabsorber (IR700) after exposure to NIR-light. NIR-PIT is realized its multidisciplinary method with the combination of the technologies in chemistry, biolody, pharmacology and physics. Presently, NIR-PIT is under the international phase III clinical trial against locoregional, recurrent head and neck SCC (HNSCC) (LUZERA-301, NCT03769506) with FDA fast track approval and expected to be clinically licensed in a few years. However, the precise mechanism of NIR-PIT is still unknown. In this review, the scheme of NIR-PIT and the mechanism of NIR-PIT is outlined.","PeriodicalId":19350,"journal":{"name":"Nippon Laser Igakkaishi","volume":"32 1","pages":"104-109"},"PeriodicalIF":0.0000,"publicationDate":"2020-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nippon Laser Igakkaishi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2530/jslsm.jslsm-41_0020","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
Abstract
Near-infrared photoimmunotherapy (NIR-PIT) is a recently developed next-generation cancer photo-target therapy that combines the specificity of intravenously injected antibodies for targeting tumors with toxicity induced by photoabsorber (IR700) after exposure to NIR-light. NIR-PIT is realized its multidisciplinary method with the combination of the technologies in chemistry, biolody, pharmacology and physics. Presently, NIR-PIT is under the international phase III clinical trial against locoregional, recurrent head and neck SCC (HNSCC) (LUZERA-301, NCT03769506) with FDA fast track approval and expected to be clinically licensed in a few years. However, the precise mechanism of NIR-PIT is still unknown. In this review, the scheme of NIR-PIT and the mechanism of NIR-PIT is outlined.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
